CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $34.1M, above the global median of $18.73M
- PositionCurrent ratio is 13.43×, higher than 95% of its Medical Devices peers (median 3.87×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.61%Above 5Y avg (0.48%)
Annual Rate
CNY 0.10Paid unknown
Payout Ratio
31.9%Sustainable
Payback Period
62.2 yr
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.45BCNY664.42M · vs all stocks (USD)
Trailing P/E
20.03xvs Medical Devices peers
Revenue (TTM)
777.21MCNY115.98M · vs all stocks (USD)
Profit Margin
28.95%vs Medical Devices peers
Beta
0.3550xvs all stocks
52-Week Change
14.58%vs all stocks
Forward Annual Dividend Yield
1.61%vs all stocks
Market Capitalization
4.45BCNY664.42M · vs all stocks (USD)
Enterprise Value
2.92BCNY435.56M · vs all stocks (USD)
Trailing P/E
20.03xvs Medical Devices peers
Forward P/E
31.05xvs Medical Devices peers
Price to Sales (TTM)
5.73xvs Medical Devices peers
Price to Book (MRQ)
1.53xvs Medical Devices peers
Enterprise to Revenue
3.76xvs Medical Devices peers
Enterprise to EBITDA
23.42xvs Medical Devices peers
Gross Margin
71.96%vs Medical Devices peers
Profit Margin
28.95%vs Medical Devices peers
Operating Margin
25.98%vs Medical Devices peers
Return on Assets (TTM)
1.65%vs Medical Devices peers
Return on Equity (TTM)
7.49%vs Medical Devices peers
Revenue (TTM)
777.21MCNY115.98M · vs all stocks (USD)
Revenue per Share (TTM)
1.08CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-32.70%vs Medical Devices peers
Gross Profit (TTM)
449.71MCNY67.11M · vs all stocks (USD)
EBITDA (TTM)
217.54MCNY32.46M · vs all stocks (USD)
Net Income (TTM)
225.01MCNY33.58M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
207.60%vs Medical Devices peers
Operating Cash Flow (TTM)
235.23MCNY35.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
228.49MCNY34.10M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1000CNYUpdated Sep 20, 2026Forward Annual Dividend Yield
1.61%vs all stocks
Trailing Annual Dividend Rate
0.1000CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
1.63%vs all stocks
5-Year Average Dividend Yield
0.48%vs all stocks
Payout Ratio
31.87%vs Medical Devices peers
Minority Interest (Equity)
30.04MCNYFY2025 · Dec 31, 2025Revenue
963.06MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
445.50MCNYFY2025 · Dec 31, 2025Gross Profit
517.56MCNYFY2025 · Dec 31, 2025Operating Income
112.08MCNY16.72M · vs all stocks (USD)
Pre-tax Income
145.48MCNYFY2025 · Dec 31, 2025Income Tax Expense
13.86MCNYFY2025 · Dec 31, 2025Net Income
131.62MCNYFY2025 · Dec 31, 2025EBIT
152.95MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
207.84MCNYFY2025 · Dec 31, 2025Research & Development
51.41MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
157.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.08MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.47MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1881CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1881CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
717.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
717.10MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
131.62MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
3.27MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
148.26MCNYFY2025 · Dec 31, 2025Free Cash Flow
86.64MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
235.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
131.62MCNYFY2025 · Dec 31, 2025Other Non-cash Items
23.24MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.87MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.47MCNYFY2025 · Dec 31, 2025Capital Expenditures
-61.62MCNYFY2025 · Dec 31, 2025Net Acquisitions
155.33MCNYFY2025 · Dec 31, 2025Purchase of Investments
-37.02MCNYFY2025 · Dec 31, 2025Sale of Investments
112.80MCNYFY2025 · Dec 31, 2025Other Investing Activity
-437.01MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-267.53MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
225.67MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-218.88MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-4.60MCNYFY2025 · Dec 31, 2025Other Financing Charges
-5.95MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.77MCNYFY2025 · Dec 31, 2025Shares Outstanding
717.01MSharesUpdated Sep 20, 2026Float Shares
543.33MSharesUpdated Sep 20, 2026% Held by Insiders
29.40%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
1.62BCNY241.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.25CNYUpdated Sep 20, 2026Total Debt (MRQ)
51.53MCNY7.69M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0175xvs Medical Devices peers
Current Ratio (MRQ)
13.43xvs Medical Devices peers
Book Value per Share (MRQ)
4.05CNYUpdated Sep 20, 2026Total Assets
3.07BCNY458.73M · vs all stocks (USD)
Total Current Assets
2.04BCNYFY2025 · Dec 31, 2025Total Liabilities
181.03MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.03BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
17.13MCNYFY2025 · Dec 31, 2025Total Current Liabilities
163.91MCNYFY2025 · Dec 31, 2025Cash
285.37MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.05MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
288.42MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.23BCNYFY2025 · Dec 31, 2025Accounts Receivable
77.66MCNYFY2025 · Dec 31, 2025Inventory
307.73MCNYFY2025 · Dec 31, 2025Accounts Payable
21.78MCNYFY2025 · Dec 31, 2025Short-term Debt
44.84MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.90MCNYFY2025 · Dec 31, 2025Long-term Debt
9.38MCNYFY2025 · Dec 31, 2025Common Stock (Book)
717.01MCNYFY2025 · Dec 31, 2025Retained Earnings
1.26BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.89BCNY431.72M · vs all stocks (USD)
52-Week Low
5.10CNYUpdated Sep 20, 202652-Week High
7.33CNYUpdated Sep 20, 202652-Week Change
14.58%vs all stocks
Beta
0.3550xvs all stocks
50-Day MA
5.98CNYUpdated Sep 20, 2026200-Day MA
6.18CNYUpdated Sep 20, 2026Avg 10-Day Volume
4.82MSharesUpdated Sep 20, 2026Avg 30-Day Volume
5.52MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.3100CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 13.43×, higher than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 13.43Industry median: 3.87Industry P95: 12.55Peers compared: 102
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $34.1M, above the global median of $18.73MNotable
Levered free cash flow (USD): 34,095,062.923Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Climb Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Weizhixiang Food Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Finolex Industries Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Songcheng Performance Development Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities